4.05
+1.25%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Sprint Bioscience
Its shares trade on Nasdaq Stockholm under the ticker SPRINT.ST. It has been listed since 7 November 2014. In the fiscal year to 31 December 2025, it reported revenue of SEK 167.2m and net income of SEK 91.7m. At that date it held total assets of SEK 136.7m and shareholders' equity of SEK 119.2m.
Sprint Bioscience AB is a pharmaceutical company, which engages in the research and development of drug for cancer. The company is headquartered in Huddinge, Stockholm. The company went IPO on 2014-11-07. The company is engaged in the development of oncology therapeutics, focusing on cancer metabolism and liquid signaling. The firm's research is based on its fragment based drug discovery (FBDD) platform, which enables rapid indentifying of molecules with properties suitable for drug development. Its pipeline is divided in two research areas: cancer metabolism and autophagy, comprising products in the phases of establishing FBDD project and in the in vivo development. The Company’s strategy involves out-licensing or collaborating at an early stage of drug discovery in order to focus on current market needs.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 7 Nov 2014
- Employees
- 33
- Website
- sprintbioscience.com ↗
Leadership
Pay as last reported
- Mr. Bjoern SjoestrandIndependent Chairman of the BoardSEK 279,000
- Mr. Johan EmilssonChief Executive Officer
- Mr. Niklas AxelssonChief Financial Officer
- Mr. Mathias SkalmstadChief Financial Officer
- Dr. Martin AnderssonHead of Research
- Ms. Anne-Marie WenthzelBusiness Development Manager
- Mr. Karen FromDirector
- Mr. Nils NordlanderDirectorSEK 140,000
- Dr. Fredrik LehmannIndependent DirectorSEK 140,000
- Mr. Svein MathisenIndependent DirectorSEK 140,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Sprint Bioscience AB has several strengths that contribute to its success in the market. Firstly, the company possesses a highly skilled and experienced research and development team. This allows them to develop innovative and high-quality products in the field of bioscience. Additionally, Sprint Bioscience has established strategic partnerships with leading pharmaceutical companies, enabling them to access resources and expertise that support their research and development efforts. Another strength is the company's strong financial position, providing them with the necessary resources to fund their projects and operations.
Weaknesses
- Despite its strengths, Sprint Bioscience AB also faces certain weaknesses that need to be addressed. One weakness is the company's reliance on a limited product portfolio. This puts them at risk in the event of product failures or market shifts. Furthermore, their relatively small size compared to some competitors may limit their ability to compete on a global scale. Additionally, the company's dependence on external collaborations and partnerships may impact their autonomy and control over their own projects.
Opportunities
- Sprint Bioscience AB operates in an industry full of opportunities that they can leverage. Firstly, the growing demand for innovative bioscience products, driven by advancements in healthcare and biotechnology, presents an opportunity for the company to expand its product offerings and increase its market share. Additionally, the increasing focus on personalized medicine and targeted therapies opens up new avenues for Sprint Bioscience to develop specialized products catering to specific patient populations. The company can also explore collaborations with academic institutions or other biotech companies to further enhance their research capabilities.
Threats
- While there are opportunities, Sprint Bioscience AB also faces certain threats that could impact their business. One major threat is the intense competition within the bioscience industry. The presence of large, established pharmaceutical companies with significant resources poses a challenge for Sprint Bioscience to maintain market share and differentiate themselves. Moreover, regulatory challenges and the need to comply with strict industry standards can create barriers to entry and hinder product development. External factors such as economic instability or changes in government policies related to healthcare and biotechnology can also impact the company's operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.